Want to see ANAB full AI Analyst Report?
Top Page
AnaptysBio
(NASDAQ:ANAB)
Select Model
Select Model
Rating:63Neutral
Price Target:
$57.00
▼(-1.72% Downside)
Action:Reiterated
Date:09/23/26
The score is driven by a meaningful financial turnaround (strong TTM profitability and improved cash flow) but tempered by a weakened balance-sheet cushion (very low equity) and only modest/weak technical momentum. Valuation helps, with a low P/E supporting the stock despite the sustainability and volatility risks implied by cash conversion and revenue concentration.
Positive Factors
Profitability and revenue inflection
The sharp move to substantial profitability and rapid revenue growth materially improves AnaptysBio’s operating profile. If its newer revenue base persists, the stronger earnings foundation can support pipeline investment and reduce reliance on external financing over the next several quarters.
Negative Factors
Reduced balance-sheet cushion
The sharp decline in equity leaves a much smaller capital cushion relative to the company’s assets and debt. That makes financial results more sensitive to earnings volatility and could constrain strategic flexibility if development spending rises or operating performance weakens.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability and revenue inflection
The sharp move to substantial profitability and rapid revenue growth materially improves AnaptysBio’s operating profile. If its newer revenue base persists, the stronger earnings foundation can support pipeline investment and reduce reliance on external financing over the next several quarters.
Read all positive factors
AnaptysBio Key Performance Indicators (KPIs)
AnaptysBio (ANAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.37B
Dividend YieldN/A
Average Volume (3M)556.82K
Price to Earnings (P/E)6.8
Beta (1Y)0.84
Revenue Growth92.92%
EPS GrowthN/A
CountryUS
Employees104
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,895,245
10 Day Avg. Volume645,476
30 Day Avg. Volume556,818
Financial Highlights & Ratios
PEG Ratio0.77
Price to Book (P/B)24.14
Price to Sales (P/S)3.83
P/FCF Ratio45.80
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue8.89
Enterprise Value/Gross Profit6.68
Enterprise Value/Ebitda22.98
Forecast
1Y Price Target
$80.00Price Target Upside37.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AnaptysBio Business Overview & Revenue Model
Company Description
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete...
How the Company Makes Money
AnaptysBio primarily generates revenue through collaboration and licensing arrangements rather than product sales, as it is a clinical-stage company with no marketed products. Its revenue model typically includes (when present under specific agree...
AnaptysBio Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
46
Neutral
Cash Flow
61
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 237.61M | 234.60M | 91.28M | 17.16M | 10.29M | 63.17M |
| Gross Profit | 316.29M | 232.18M | -72.56M | -115.13M | -78.51M | -35.32M |
| EBITDA | 91.91M | 69.25M | -92.74M | -154.70M | -105.26M | -55.71M |
| Net Income | 195.72M | -13.23M | -145.23M | -163.62M | -128.72M | -57.80M |
Balance Sheet | ||||||
| Total Assets | 316.98M | 364.39M | 483.83M | 452.39M | 610.38M | 643.07M |
| Cash, Cash Equivalents and Short-Term Investments | 164.14M | 311.64M | 385.37M | 390.90M | 441.24M | 548.10M |
| Total Debt | 269.59M | 14.11M | 369.46M | 17.81M | 19.45M | 20.95M |
| Total Liabilities | 306.40M | 327.19M | 412.97M | 364.29M | 348.28M | 286.64M |
| Stockholders Equity | 10.59M | 37.21M | 70.87M | 88.10M | 262.10M | 356.43M |
Cash Flow | ||||||
| Free Cash Flow | 18.07M | 19.61M | -135.69M | -121.61M | -73.95M | -47.29M |
| Operating Cash Flow | 18.08M | 19.70M | -135.34M | -120.80M | -73.59M | -45.92M |
| Investing Cash Flow | 219.33M | 228.03M | 95.40M | 144.75M | -394.85M | 38.84M |
| Financing Cash Flow | -147.88M | -132.61M | 127.05M | -59.30M | 44.02M | 252.30M |
AnaptysBio Technical Analysis
Negative
58.00
Price Trends
54.34
Negative
56.10
Negative
49.18
Negative
Market Momentum
-2.45
Positive
26.85
Positive
12.46
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Negative. The current price of 58 is above the 20-day moving average (MA) of 50.96, above the 50-day MA of 54.34, and above the 200-day MA of 49.18, indicating a bearish trend. The MACD of -2.45 indicates Positive momentum. The RSI at 26.85 is Positive, neither overbought nor oversold. The STOCH value of 12.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANAB.
AnaptysBio Risk Analysis
AnaptysBio disclosed 49 risk factors in its most recent earnings report. AnaptysBio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AnaptysBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.37B | 6.81 | 2515.23% | ― | 92.92% | ― | |
57 Neutral | $1.83B | -11.35 | -28.66% | ― | -28.56% | 10.25% | |
54 Neutral | $884.95M | -16.44 | -36.15% | ― | ― | 8.14% | |
54 Neutral | $1.84B | -12.77 | -72.07% | ― | -69.78% | -106.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $999.43M | -4.61 | -52.89% | ― | ― | 3.56% | |
44 Neutral | $560.00M | -5.71 | -38.46% | ― | -87.03% | -179.91% |
* Healthcare Sector Average
ANAB
AnaptysBio
45.95
24.31
112.38%
XNCR
Xencor
24.63
10.67
76.43%
CTMX
CytomX Therapeutics
2.57
-0.83
-24.41%
CRVS
Corvus Pharmaceuticals
10.52
3.41
47.96%
ZYME
Zymeworks
25.79
7.68
42.41%
CGEM
Cullinan Management
15.53
7.70
98.34%
AnaptysBio Corporate Events
Executive/Board ChangesShareholder Meetings
AnaptysBio Shareholders Back Board, Governance and Incentives
Positive
Aug 11, 2026
On August 11, 2026, AnaptysBio, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected Class III directors Hollings Renton and John P. Schmid to three-year terms extending to the 2029 Annual Meeting. The voting results showe...
Business Operations and StrategyLegal Proceedings
AnaptysBio Enters Key Post-Trial Phase in Tesaro Dispute
Neutral
Jul 30, 2026
In November 2025, AnaptysBio filed a Verified Complaint in the Delaware Court of Chancery alleging that Tesaro materially breached their Collaboration and Exclusive License Agreement and that GlaxoSmithKline, Tesaro’s corporate parent, torti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.